Diabetic retinopathy (DR) is the leading cause of legal blindness in the United States, and with the growing epidemic of diabetes, a global increase in the incidence of DR is inevitable, so it is of utmost importance to identify the most cost-effective tools for DR screening. Emerging technology may provide advancements to offset the burden of care, simplify the process, and provide financially responsible methods to safely and effectively optimize care for patients with diabetes mellitus (DM). We review here currently available technology, both in production and under development, for DR screening. Preliminary results of smartphone-based devices, "all-in-one" devices, and alternative technologies are encouraging, but are largely pending verification of utility when used by nonophthalmic personnel. Further research comparing these devices to current nonportable telemedicine strategies and clinical fundus examination is necessary to validate these techniques and to potentially overcome the poor compliance around the globe of current strategies for DR screening.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773980 | PMC |
http://dx.doi.org/10.1177/1932296816629158 | DOI Listing |
J CME
January 2025
DKBmed, New York, NY, USA.
Diabetic retinopathy (DR) is a public health issue affecting millions in the United States and Europe. However, despite strong recommendations for screening at regular intervals by many professional societies, including the American Diabetes Association and the American Academy of Ophthalmology, screening rates remain suboptimal, with only 50-70% of patients with diabetes adhering to recommended annual eye exams. Barriers to screening include lack of awareness, socioeconomic factors, health care system fragmentation, and workforce shortages, among others.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Ophthalmology, Taichung Veterans General Hospital, No.1650, Sec. 4, Taiwan Blvd., Xitun Dist., Taichung, Taiwan.
Diabetic retinopathy (DR) is a leading cause of vision loss among adults. This study evaluates Optical Coherence Tomography Angiography (OCTA) vessel density (VD) as a marker for DR in diabetes mellitus (DM) patients. An observational study was conducted with 47 type 2 DM patients and 21 healthy controls.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Ophthalmology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Gyongchun-ro 153, Guri, Gyeonggi-do, South Korea.
To evaluate the effectiveness of postoperative intravitreal bevacizumab (IVB) in preventing neovascular glaucoma (NVG) and identify associated risk factors in patients with proliferative diabetic retinopathy (PDR) undergoing phacovitrectomy. Patients with PDR who underwent phacovitrectomy were enrolled and categorized into two subgroups based on their postoperative treatment regimen: one group received IVB within 2 months following phacovitrectomy (Group 1); the other did not receive IVB during this period (Group 2). A comparative analysis evaluated the distinguishing characteristics of the two groups after 1:1 propensity score matching.
View Article and Find Full Text PDFEndocr Metab Immune Disord Drug Targets
January 2025
Beijing University of Chinese Medicine, Beijing, China.
Background: Research on RNA in diabetic retinopathy (DR) has received increasing attention in recent years. However, there is a lack of comprehensive and systematic research on the current status and future direction of RNA research in DR. Therefore, this study used bibliometric analysis to summarize the global trends and current status of DR RNA research to date.
View Article and Find Full Text PDFPharmaceuticals (Basel)
November 2024
Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.
Early stages of diabetic retinopathy are currently considered an unmet medical need due to the lack of effective treatments beyond proper monitoring and control of glycemia and blood pressure. Sitagliptin eye drops have emerged as a new therapeutic approach against early stages of the disease, as they can prevent its main hallmarks, including both neurodegeneration and microvascular impairment. Interestingly, all of these effects occur without any glycemic systemic improvement.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!